Jose Baselga
Gordon McVie
REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Neoadjuvant trastuzumab for patients with HER2-positive inflammatory breast cancer has shown significantly higher pathological response rates compared with chemotherapy alone. This is according to data presented at the ECCO meeting from the NOAH trial that randomly assigned more than 60 patients to receive chemotherapy plus trastuzumab or chemotherapy alone. Sarah Maxwell heard from Jose Baselga, who thinks this should be a new standard of care, and Gordon McVie.
JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Neoadjuvant trastuzumab for patients with HER2-positive inflammatory breast cancer has shown significantly higher pathological response rates compared with chemotherapy alone. This is according to data presented at the ECCO meeting from the NOAH trial that randomly assigned more than 60 patients to receive chemotherapy plus trastuzumab or chemotherapy alone. Sarah Maxwell heard from Jose Baselga, who thinks this should be a new standard of care, and Gordon McVie.
Chris Twelves
Oral Capecitabine: As Good as FU/Leucovorin for Stage III Colorectal Cancer: X-ACT Trial 5-Year Data
REFERENCE: ABSTRACT LB1, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CHRIS TWELVES, Cancer Research UK, Leeds
For adjuvant therapy in stage III colon cancer, capecitabine may be just as effective as standard FU/leucovorin therapy. A randomized study presented at ECCO compared capecitabine with the gold standard treatment. Sarah Maxwell asked Chris Twelves about the X-ACT trial 5-year data and their implications.
CHRIS TWELVES, Cancer Research UK, Leeds
For adjuvant therapy in stage III colon cancer, capecitabine may be just as effective as standard FU/leucovorin therapy. A randomized study presented at ECCO compared capecitabine with the gold standard treatment. Sarah Maxwell asked Chris Twelves about the X-ACT trial 5-year data and their implications.
Christian Manegold
Gordon McVie
Bevacizumab in Non–Small-Cell Lung Cancer: Positive Results, But Will Doctors Use It?
REFERENCE: ABSTRACT 6503, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CHRISTIAN MANEGOLD, Heidelberg University, Manheim
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Bevacizumab has been shown to improve progression-free survival in patients with advanced non–small-cell lung cancer when used together with gemcitabine and cisplatin; but are doctors ready to embrace this molecular therapy? Data on these patients was initially released at the ASCO meeting, and after some reaction at ECCO in Barcelona, Peter Goodwin spoke with lead investigator Christian Manegold, while Gordon McVie gave his thoughts on the issue.
CHRISTIAN MANEGOLD, Heidelberg University, Manheim
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Bevacizumab has been shown to improve progression-free survival in patients with advanced non–small-cell lung cancer when used together with gemcitabine and cisplatin; but are doctors ready to embrace this molecular therapy? Data on these patients was initially released at the ASCO meeting, and after some reaction at ECCO in Barcelona, Peter Goodwin spoke with lead investigator Christian Manegold, while Gordon McVie gave his thoughts on the issue.
Paul de Souza
Temsirolimus Alone: Best for Patients With Poor Prognosis Renal Cell Carcinoma
REFERENCE: ABSTRACT 4011, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CHRIS TWELVES, Cancer Research UK, Leeds
A randomized phase III study from Australia presented at the ECCO meeting in Barcelona has shown that temsirolimus alone is best for patients with advanced renal cell carcinoma and poor prognostic features. The study randomly assigned 600 patients to receive interferon-ï¡, temsirolimus, or a combination of the two. Sarah Maxwell spoke with chief investigator Paul de Souza in Barcelona.
CHRIS TWELVES, Cancer Research UK, Leeds
A randomized phase III study from Australia presented at the ECCO meeting in Barcelona has shown that temsirolimus alone is best for patients with advanced renal cell carcinoma and poor prognostic features. The study randomly assigned 600 patients to receive interferon-ï¡, temsirolimus, or a combination of the two. Sarah Maxwell spoke with chief investigator Paul de Souza in Barcelona.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.
